Oppenheimer Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Maintains Target Price $29

Oppenheimer analyst Francois Brisebois maintains $Avadel Pharmaceuticals(AVDL.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate o

moomoo NewsJun 17 08:31 ET · Ratings

Rodman & Renshaw Initiates Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Announces Target Price $27

Rodman & Renshaw analyst Brandon Folkes initiates coverage on $Avadel Pharmaceuticals(AVDL.US)$ with a buy rating, and sets the target price at $27.According to TipRanks data, the analyst has a succes

moomoo NewsJun 11 17:31 ET · Ratings

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

European equities traded in the US as American depositary receipts were higher Wednesday morning, rising 0.93% to 1,436.34 on the S&P Europe Select ADR Index. From continental Europe, the gainers were

MT NewswiresJun 5 11:10 ET

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of

GlobeNewswireMay 30 08:00 ET

Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –– Presentations highlight Avadel's continued commitment to address gaps in narcolepsy c

BenzingaMay 22 08:13 ET

Avadel Pharmaceuticals: Appointment Effective May 17, 2024 >AVDL

Avadel Pharmaceuticals: Appointment Effective May 17, 2024 >AVDL

Dow JonesMay 21 07:05 ET